Iruplinalkib: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 18, p. 1717, doi. 10.1007/s40265-023-01970-w
- By:
- Publication type:
- Article
Works matching IS 00126667 AND DT 2023 AND VI 83 AND IP 18
Results: 10
1
2
Correction to: Motixafortide: First Approval.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
3
Correction: Elacestrant: First Approval.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
4
Nedosiran: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 18, p. 1729, doi. 10.1007/s40265-023-01976-4
- By:
- Publication type:
- Article
5
Gepirone Extended-Release: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 18, p. 1723, doi. 10.1007/s40265-023-01975-5
- By:
- Publication type:
- Article
6
Acknowledgement to Referees.
- Published in:
- Drugs, 2023, v. 83, n. 18, p. 1645, doi. 10.1007/s40265-023-01972-8
- Publication type:
- Article
7
Momelotinib: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 18, p. 1709, doi. 10.1007/s40265-023-01964-8
- By:
- Publication type:
- Article
8
HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic.
- Published in:
- Drugs, 2023, v. 83, n. 18, p. 1677, doi. 10.1007/s40265-023-01963-9
- By:
- Publication type:
- Article
9
Aetiology of Significant Liver Test Abnormalities in a Single-Centre Cohort of People with Cystic Fibrosis Exposed to Elexacaftor/Tezacaftor/Ivacaftor, Utilizing the Updated RUCAM.
- Published in:
- Drugs, 2023, v. 83, n. 18, p. 1699, doi. 10.1007/s40265-023-01969-3
- By:
- Publication type:
- Article
10
Current and Emerging Treatment Options for Uterine Fibroids.
- Published in:
- Drugs, 2023, v. 83, n. 18, p. 1649, doi. 10.1007/s40265-023-01958-6
- By:
- Publication type:
- Article